- Subjects with proven or probable invasive fungal infections including subjects who
have failed to respond to, or have an intolerance to other approved antifungal
treatments and with approval for salvage treatment by Principal Investigator and
- Subjects who are showing continuing improvement with other antifungal agents,
including amphotericin B, itraconazole, nystatin, fluconazole, flucytosine and
- Subjects with an invasive fungal infection caused by a fungus (such as Mucor) that is
not in the antifungal spectrum of voriconazole.